Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, ...

Nonclinical protocol study design accepted by FDA Study to commence in First Quarter 2026King of Prussia, Pennsylvania--(Newsfile Corp. - December 23, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) ...

SHANGHAI and SANTA BARBARA, Calif., Dec. 15, 2025 /PRNewswire/ -- Rona Therapeutics, a clinical-stage RNAi company, today ...

Explore the potential of gene therapy as a groundbreaking approach to curing diseases, beyond traditional pharmacological ...

EXECUTIVE SUMMARYVial's INHBE siRNA is a first-in-class, liver-targeted (GalNAc-conjugated) siRNA therapy that silences INHBE ...

Alnylam Pharmaceuticals, Inc. , the leading RNAi therapeutics company, today announced the planned expansion of its state-of-the-art manufacturing facility in Norton, Massachusetts. The Company is ...

HELIOS-B is a global, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of AMVUTTRA (R) in adult patients with wtATTR or hATTR amyloidosis with ...

Arrowhead Pharma doses first subjects in phase 1/2a study of ARO-MAPT to treat Alzheimer’s disease and other tauopathies: Pasadena, California Thursday, December 11, 2025, 12:00 ...

TheFly reported on December  16 that Oppenheimer raised its price target on WVE to $32 from $24 while maintaining an ...

Phio Pharmaceuticals ( ($PHIO) ) has provided an announcement. On December 23, 2025, Phio Pharmaceuticals announced that the U.S. Food and Drug ...

Following a single subcutaneous 240 mg dose, WVE-007 (INHBE GalNAc-siRNA) improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% ...

Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today announced that Craig Tooman, who has ...